Tralokinumab治疗中重度特应性皮炎成人患者长达4年的疗效
本项事后 interim 分析纳入在ECZTRA 1或2完成52周tralokinumab治疗并进入ECZTEND开放标签扩展试验的347例中重度特应性皮炎成人患者。至ECZTEND第152周,52.6%达到IGA 0/1,84.5%达到EASI-75,且71.4%在16至152周间≥80%天数维持EASI≤7,提示长期疾病控制稳定。
要点
- Tralokinumab联合按需TCS/TCI治疗4年可使部分中重度AD患者达到无至轻度疾病状态。
- 第152周时84.5%患者达到EASI-75,68.0%达到瘙痒NRS≤4,79.0%达到DLQI≤5。
- 71.4%患者在16至152周间≥80%天数维持EASI≤7,提示疗效稳定。
核心结论
- 在完成母试验1年治疗并进入ECZTEND的成人中重度AD亚组中,tralokinumab联合按需TCS/TCI治疗长达4年可提供长期稳定的疾病控制,达到无至轻度疾病状态。
研究设计与样本
- 事后 interim 分析纳入347例在ECZTRA 1或ECZTRA 2完成52周tralokinumab治疗后进入ECZTEND开放标签扩展试验、且在数据截止前接受研究药物≥152周的成人中重度AD患者。
- ECZTEND中患者接受tralokinumab联合按需局部糖皮质激素/钙调神经磷酸酶抑制剂(TCS/TCI)治疗。
主要发现
- ECZTEND第152周,52.6%(95%CI 45.2; 59.8)患者达到IGA 0/1。
- 84.5%(95%CI 78.4; 89.1)患者达到EASI较母试验基线改善≥75%。
- 84.5%(95%CI 78.4; 89.1)、68.0%(95%CI 60.8; 74.5)和79.0%(95%CI 72.1; 84.6)患者分别达到EASI≤7、最差周瘙痒NRS≤4和DLQI≤5。
- 71.4%(95%CI 66.3; 76.0)患者在ECZTEND第16至152周间≥80%天数维持EASI≤7。
- ECZTEND期间28.5%患者停药,其中7.5%因疗效不足、5.8%因不良事件;最常见不良事件包括鼻咽炎(IR=13.6)、上呼吸道感染(IR=4.4)和结膜炎(IR=2.3)。
临床怎么用
- 对于完成1年tralokinumab治疗的中重度AD成人患者,继续治疗至4年可维持较高的无至轻度疾病状态比例。
- 治疗期间可联合按需TCS/TCI,并关注鼻咽炎、上呼吸道感染和结膜炎等不良事件。
局限性
- 本分析为事后 interim 分析,仅纳入完成母试验52周治疗并进入ECZTEND的亚组患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Atopic dermatitis (AD) is a relapsing and remitting skin disease often requiring long-term treatment. Tralokinumab, a monoclonal antibody specifically neutralizing interleukin-13, is approved for moderate-to-severe AD treatment in multiple countries. OBJECTIVES: Assess long-term efficacy of tralokinumab in adults with moderate-to-severe AD treated for up to 4 years. METHODS: This post hoc interim analysis included the subgroup of patients (n = 347) who completed 52 weeks of tralokinumab in the Phase 3 ECZTRA 1 or ECZTRA 2 (NCT03131648/NCT03160885) trials and subsequently enrolled in the open-label extension trial ECZTEND (NCT03587805; receiving tralokinumab plus optional topical corticosteroids/calcineurin inhibitors [TCS/TCI]) ≥152 weeks prior to data cut-off (30-April-2022). RESULTS: At ECZTEND Week 152, 52.6% (95% CI 45.2; 59.8) of patients achieved Investigator's Global Assessment 0/1 (clear or almost clear skin) and 84.5% (95% CI 78.4; 89.1) achieved ≥75% improvement in Eczema Area and Severity Index (EASI) from parent trial baseline; additionally, 84.5% (95% CI 78.4; 89.1), 68.0% (95% CI 60.8; 74.5) and 79.0% (95% CI 72.1; 84.6) reached EASI ≤7 (no-to-mild disease), Worst Weekly Pruritus Numeric Rating Scale ≤4 (no-to-mild itch) and Dermatology Life Quality Index ≤5 (no-to-small effect on quality of life), respectively. Responses were stable over time, with 71.4% (95% CI 66.3; 76.0) of patients maintaining EASI ≤7 at ≥80% of days between Week 16 and 152 in ECZTEND. During ECZTEND, 28.5% of patients discontinued: 7.5% due to lack of efficacy and 5.8% due to adverse events (AEs). The most frequently reported AEs in ECZTEND were consistent with the known safety profile of tralokinumab, including nasopharyngitis (IR = 13.6), upper respiratory tract infection (IR = 4.4) and conjunctivitis (IR = 2.3). CONCLUSIONS: These data suggest that tralokinumab plus optional TCS/TCI provides long-term stable disease control, equivalent to no-to-mild disease, in a subgroup of adults with moderate-to-severe AD who completed 1 year of treatment in parent trials and up to 3 years in ECZTEND. Atopic dermatitis (AD) is a long‐lasting, itchy skin disease in which patients often experience periods of worsening symptoms that can negatively impact their quality of life. Tralokinumab is a medication approved for treating adults and adolescents with moderate‐to‐severe AD. This study looked at the impact of tralokinumab in adults with moderate‐to‐severe AD who received 1 year of treatment in a large clinical trial (ECZTRA 1 or 2) and then joined a follow‐up trial, ECZTEND, at least 3 years before data were collected. After 4 years of tralokinumab treatment, 85% of these patients had clear or mild disease (measured by EASI ≤7); 68% had no or mild itch (measured by Worst Weekly Pruritus NRS ≤4); and 79% had no or small impact of AD on quality of life (measured by DLQI ≤5). Because AD symptoms fluctuate over time, we also examined how consistently individual patients met these treatment goals. More than 70% of patients examined here maintained clear or mild disease with minimal fluctuations, defined as keeping the response for at least 80% of days during tralokinumab treatment in ECZTEND. Reported side effects were mostly mild and were consistent with a recent analysis of multiple clinical trials including many more patients.13 In summary, tralokinumab treatment provided stable control of AD signs and symptoms in those adults with moderate‐to‐severe AD who completed at least 1 year of treatment prior to joining ECZTEND. These results show that tralokinumab can be an effective and well‐tolerated long‐term treatment option for patients with AD.
引用
- Gooderham M, Ameen M, Hong HC, et al. Efficacy of up to 4 years of tralokinumab in adults with moderate-to-severe atopic dermatitis. J Eur Acad Dermatol Venereol. 2025. PMID: 41217071. doi:10.1111/jdv.70165
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。